BEDFORD, Mass., Jan. 7, 2011 /PRNewswire/ — Hologic, Inc.
(Hologic or the Company) (Nasdaq:
HOLX), a leading developer, manufacturer and supplier of
premium diagnostics, medical imaging systems and surgical products
dedicated to serving the healthcare needs of women, announced today
it has acquired Interlace Medical, Inc. (Interlace), the developer
and manufacturer of the MyoSure hysteroscopic tissue removal system
(MyoSure). Interlace’s operations will be integrated within
Hologic’s GYN Surgical Products division.
“The acquisition of Interlace is consistent with our strategy to
strengthen our leadership position in women’s healthcare,” said
Steve Williamson, Senior Vice President and General Manager, GYN
Surgical Products. “MyoSure is an innovative technology that is
designed to safely and easily remove fibroids and polyps that
plague millions of women. This product is a natural extension of
our industry-leading OB/GYN product portfolio which now provides
women with minimally-invasive treatment options – from their child
bearing years to menopause. The strong clinical performance and
ease of use of the MyoSure device make it a natural fit with our
NovaSure endometrial ablation and Adiana permanent contraception
product lines.”
Interlace, a privately-held company headquartered in Framingham,
Massachusetts, is dedicated to developing innovative technologies
to treat common gynecological diseases for improved patient
outcomes while simplifying physician adoption and reducing the cost
of healthcare.
The purchase price for the transaction was $125 million in cash,
subject to adjustment, plus two annual contingent payments. The
contingent payments will be payable in cash and each will be
calculated as a multiple of the incremental revenue growth over the
prior year.
About MyoSureIn the United States, there are approximately 5
million women sufferin
‘/>”/>
